Prognostic value of hibernating myocardium and cardiac remodeling using gated 99mTc-MIBI SPECT and gated 18F-FDG PET in patients with ischemic heart failure and diabetes

Author:

Duan Lili1,Meng Jingjing1,Zheng Yaqi1,Lu Yao1,Tian Jing1,Bai Yujie1,Zhang Xiaoli1ORCID

Affiliation:

1. Beijing An Zhen Hospital: Capital Medical University Affiliated Anzhen Hospital

Abstract

Abstract Background The prognostic value of hibernating myocardium (HM) and left ventricular (LV) remodeling in patients with ischemic heart failure (IHF) and diabetes mellitus (DM) remains undetermined. Therefore, we aimed to evaluate the prognostic value of HM and LV remodeling in such patients. Methods A total of 333 consecutive patients with coronary artery disease (CAD) and LV ejection fraction ≤ 35% who underwent gated 99mTc-MIBI single photon emission computed tomography (SPECT) myocardial perfusion imaging (G-MPI) and gated 18F-FDG positron emission tomography (PET) myocardial metabolic imaging at Beijing Anzhen Hospital between April 2016 and February 2019 were enrolled and followed up for a median of 3.6 (range, 0.3–5.1) years. Patients were divided into DM (n = 141) and non-DM (n = 192) groups. HM + was defined as HM > 10%. LV remodeling + was defined as end-systolic volume index ≥ 92 mL/m2 by G-MPI. The endpoint was all-cause death. Results More HM was observed in DM than that in non-DM group (18.0 [10.0, 27.0]% vs. 10.0 [0.5, 20.0]%, P < 0.001, respectively). In DM patients, survival for patients with LV remodeling was lower than that for those without LV remodeling (55.1% ± 10.0% vs. 79.9% ± 7.1%, P = 0.007, respectively), but there was no significant difference in survival between HM + and HM- (P > 0.05). Revascularization was associated with better long-term survival than medical therapy in patients with HM+ (DM+, 87.1% ± 7.6% vs. 45.3% ± 10.4%; DM-, 95.7% ± 2.9% vs. 41.9% ± 10.7%, all P value < 0.001), or LV remodeling+ (DM+, 95.2% ± 4.6% vs. 40.3% ± 10.9%, P = 0.001; DM-, 87.1% ± 9.6% vs. 52.3% ± 8.7%, P = 0.004). Conclusions HM may be more prevalent in IHF patients with DM compared with those non-DM. Assessing HM and LV remodeling using nuclear imaging techniques allowed for risk stratification and guided strategy decision-making in DM patients.

Publisher

Research Square Platform LLC

Reference44 articles.

1. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC;McDonagh TA;Rev Esp Cardiol (Engl Ed),2022

2. Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes;Park JJ;Diabetes Metab J,2021

3. Mesenchymal Stem Cell Therapy for Patients with Ischemic Heart Failure- Past, Present, and Future;Liang P;Curr Stem Cell Res Ther,2021

4. Global estimates of diabetes prevalence for 2013 and projections for 2035;Guariguata L;Diabetes Res Clin Pract,2014

5. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology;Seferović PM;Eur J Heart Fail,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3